PT  - JOURNAL ARTICLE
AU  - Canbay, Fatma
AU  - Merzi Öztürk, Ayperi
AU  - Canbakan, Sema
AU  - Demirağ, Funda
AU  - Ertürk, Hakan
TI  - Late Breaking Abstract - Factors affecting recurrence in early stage lung adenocarcinoma
AID  - 10.1183/13993003.congress-2023.PA2203
DP  - 2023 Sep 09
TA  - European Respiratory Journal
PG  - PA2203
VI  - 62
IP  - suppl 67
4099  - https://publications.ersnet.org//content/62/suppl_67/PA2203.short
4100  - https://publications.ersnet.org//content/62/suppl_67/PA2203.full
SO  - Eur Respir J2023 Sep 09; 62
AB  - In this study 307 cases with early stage diagnosis of adenocarcinoma according to TNM 7 between 2011-2014 were retrospectively evaluated. Preoperative and postoperative clinicopathologic charecteristics were reviewed.Postoperative early stage 202 adenocarcinoma cases were included in the study.202 cases were divided into two groups as recurrent(n:83) and non-recurrent(n:119) groups.Age,smoking,solid dominant type adenocarcinoma histological pattern,high SUV involvement,no adjuvant treatment, pre-operative and post-operative tumor size(larger than 2.95 and 3.05, respectively),pre-post-operative advanced stage,post-operative N stage and lymphovascular invasion were found to be poor prognostic factors on recurrence.In the study,it was determined that frosted glass characterization on CT,receiving adjuvant treatment and low SUV involvement decreased the likelihood of recurrence,chemotherapy and low SUV involvement significantly delayed the time until recurrence.The limitations of our study were its long duration and the publication of TNM 8 staging immediately after the study.Therefore, we restaged our cases according to TNM 8.İn the new staging; we observed that tumors with ground glass characteristics,patients who were still smoking,patients with preoperative T1c and postoperative T1b, patients with preoperative stage 1B, and patients with lymphatic invasion were more likely to recur in the new staging. FootnotesCite this article as: European Respiratory Journal 2023; 62: Suppl. 67, PA2203.This abstract was presented at the 2023 ERS International Congress, in session “Inflammatory endotyping: the macrophage across disease areas”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).